- Home
- PETS vs ALVR Comparison
PETS vs ALVR Comparison
Compare PETS & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- ALVR
- Stock Information
- Founded
- PETS 1996
- ALVR 2013
- Country
- PETS United States
- ALVR United States
- Employees
- PETS N/A
- ALVR N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PETS Consumer Staples
- ALVR Health Care
- Exchange
- PETS Nasdaq
- ALVR Nasdaq
- Market Cap
- PETS 82.0M
- ALVR 87.7M
- IPO Year
- PETS N/A
- ALVR 2020
- Fundamental
- Price
- PETS $4.70
- ALVR $0.57
- Analyst Decision
- PETS Sell
- ALVR Sell
- Analyst Count
- PETS 2
- ALVR 5
- Target Price
- PETS $3.50
- ALVR $1.00
- AVG Volume (30 Days)
- PETS 379.1K
- ALVR 545.6K
- Earning Date
- PETS 11-06-2024
- ALVR 11-12-2024
- Dividend Yield
- PETS N/A
- ALVR N/A
- EPS Growth
- PETS N/A
- ALVR N/A
- EPS
- PETS N/A
- ALVR N/A
- Revenue
- PETS $259,343,000.00
- ALVR N/A
- Revenue This Year
- PETS N/A
- ALVR N/A
- Revenue Next Year
- PETS $3.36
- ALVR N/A
- P/E Ratio
- PETS N/A
- ALVR N/A
- Revenue Growth
- PETS N/A
- ALVR N/A
- 52 Week Low
- PETS $2.90
- ALVR $0.53
- 52 Week High
- PETS $7.94
- ALVR $2.49
- Technical
- Relative Strength Index (RSI)
- PETS 54.12
- ALVR 36.81
- Support Level
- PETS $4.08
- ALVR $0.53
- Resistance Level
- PETS $5.90
- ALVR $1.05
- Average True Range (ATR)
- PETS 0.36
- ALVR 0.11
- MACD
- PETS 0.03
- ALVR -0.04
- Stochastic Oscillator
- PETS 37.82
- ALVR 7.50
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.